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glial, neuronal and endothelial markers demonstrating pluripo-
tency of differentiation potential. These findings point towards
an essential role of CD133/Musashi-1+ cells in glioma biology
making these cells a potential target for future therapies. On the
other hand, stem cells are currently evaluated as potential carriers
of anti-glioma therapies. Therefore, the second aim of our studies
was to assess intracerebral distribution patterns of mesenchymal
stroma cells (MSC) after local versus systemic application. Human
MSC (hMSC) were isolated from bone marrow biopsies carried out
for haematological indications. U373-GFP gliomas were generated
by orthotopic implantation. After local application of hMSC,
migration of hMSC towards the tumor was observed. In a second
setting, intravenously administered MSC transfected with a RFP/
Tie-2 promotor gene showed extensive tropism to the glioma.
RFP expression indicated integration of MSC into the intratumoral
vasculature. Therefore, MSC might be valuable candidates as car-
riers for an anti-tumor, especially an anti-vascular gene therapy.
Altogether, stem cells might play roles in the ‘‘cause’’ as well as
in the ‘‘cure’’ of glioma.
doi:10.1016/j.ejcsup.2006.04.049
S49. TARGETED DELIVERY OF CHEMOTHERAPY USING
MICROENCAPSULATED CELLS FOR GDEPT
J.-Matthias Lo¨hr. Clinical Cooperation Unit for Molecular Oncology
(dkfz E180), Department of Medicine II, Mannheim Medical Faculty,
University of Heidelberg, Germany.
Some of the most potent cytotoxic drugs, e.g. ifosfamide, are
hampered in their effectiveness in certain cancers due to severe
side effects in elder patients. A way to circumvent this problem
is to employ gene directed enzyme prodrug therapy by delivering
a second site of drug activation at the tumor site. This concept
was developed using ifosfamide as the prodrug and the metabol-
ising cytochrome P450 subenzyme CYP2B1 for conversion. The
gene was transfected in 293 cells. To protect the genetically mod-
ified cells from the host immune system and, conversely, to pro-
tect the host from the allogenic cells, those were
microencapsulated in sodium cellulose (diameter  0.8 mm). In
an experimental setting, the microcapsules containing CYP2B1
expressing cells were directly injected in pre-established human
pancreatic adenocarcinomas on nude mice. After treatment with
low-dose ifosfamide, 20% CR was achieved. Identical results were
obtained in a syngenic rat pancreatic carcinoma model. Further,
this experimental approach has very successfully been applied
to experimental peritoneal carcinomatosis as well as naturally
occurring breast carcinomas in dogs. For clinical use, a feasibility
study in pigs demonstrated the safety of agiographic intra-arterial
placement into a pancreatic artery. After completion of IRB and
registration with authorities, a clinical phase I/II study in patients
with inoperable pancreatic adenocarcinoma was performed. The
concept proved to be safe. 2/14 patients demonstrated a partial
remission, the reminder was stable. Mean OS was 44 weeks,
one year survival 32%.
doi:10.1016/j.ejcsup.2006.04.050
S50. DEVELOPING STRATEGIES FOR TUMOR VACCINATION
Andreas Mackensen. Department of Hematology/Oncology,
University of Regensburg, Germany.
Vaccination against cancer has had a variable history, with
claims of success often fading into disappointment. The reasons
for this include poor vaccine design, inadequate understanding
of the nature of the immune response, and a lack of objective
measures to evaluate performance. The characterization of
tumor-associated antigens (TAAs) recognized by human T lym-
phocytes in a MHC-restricted fashion has opened new possibili-
ties for specific vaccine approaches to the treatment of human
cancers. Recent findings include vaccine formulation, relevant
knowledge concerning mechanisms of induction of effective
immunity from preclinical models, and translation into clinical
trials. We now have novel vaccine strategies to activate specific
attack on tumor cells and we understand more about activation
and regulation of immunity against cancer (co-stimulation versus
co-inhibition, regulatory T cells). We also have modern assays
using surrogate markers (MHC multimer analysis, IFN-c Elispot
assay) to correlate with clinical effects. Although early clinical
vaccine trials based on synthetic peptides, proteins, ‘naked’
DNA, tumor-RNA, dendritic cells, and recombinant vaccinia
viruses indicate that vaccines can induce immune responses
and tumor regression in some cancer patients, careful study
design and use of standardized clinical and immunological crite-
ria are needed. Basic principles of tumor vaccination and clinical
trials will be discussed.
doi:10.1016/j.ejcsup.2006.04.051
S51. MOLECULAR STAGING OF THYROID CANCERS AND
ASSOCIATED FAMILIAL SYNDROMES – CONSEQUENCES
FOR SCREENING AND THERAPY
Theresia Weber. Department of Surgery, University of Heidelberg,
Germany.
Disseminated tumor cells in tissue, blood or bone marrow sam-
ples of patients with thyroid carcinoma are detectable by PCR
assays by using different molecular tumor markers. The aim of
our study was to correlate the results of molecular staging with
the patients’ follow-up.
Patients and Methods: Eighty-seven tumor, 43 blood and 14 bone
marrow samples of patients with thyroid carcinomas were
obtained during surgery and subjected to Cytokeratin 20 (CK20)
and PreproGastrin-releasing peptide (PreproGRP) PCR systems.
Results: An expression of CK20 transcripts was detected in all of
the medullary thyroid carcinomas (MTC), 63% of follicular thyroid
carcinomas (FTC), 43% of papillary (PTC) and 17% of anaplastic
(ATC) carcinomas . In FTC and PTC an expression of CK20 was
seen in 54% in primary tumors and in 42% in soft tissue or lymph
node recurrence. 75% of the patients with CK20-positive FTC were
disease-free at follow-up compared to none of the patients with
CK20-negative FTC. PreproGRP was found in 100% of MTC tissue
samples. Overall, disseminated tumor cells of CK20-positive
carcinomas were detected in 33% of the blood samples. In MTC,
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preproGRP transcripts were found in 28% of the blood samples.
The detection of a hematogenic tumor cell spread with preproGRP
in MTC correlated significantly with advanced tumor categories.
CK20 transcripts were detected in 75% of the blood samples of
patients with thyroid carcinoma and distant metastases. More-
over disseminated tumor cells were detected in 21% of the bone
marrow samples with CK20-PCR and 13% with preproGRP (only
for MTC).
Conclusion: Both assays are sensitive enough to detect dissemi-
nated thyroid carcinoma cells in blood and bone marrow sam-
ples. However, the prognostic relevance of these disseminated
tumor cells is not completely understood and has to be addressed
in further investigations.
doi:10.1016/j.ejcsup.2006.04.052
S52. Pdcd4 TARGETS eIF4A TO INHIBIT TRANSLATION,
TRANSCRIPTION, TUMORIGENESIS, AND INVASION
Nancy H. Colburn, Hsin-Sheng Yang, Aaron Jansen. Laboratory of
Cancer Prevention, National Cancer Institute, Frederick, MD 21702,
USA.
Despite its name, Programmed Cell Death 4 (Pdcd4) may or may
not induce apoptosis. Pdcd4 was discovered as a highly expressed
gene in mouse JB6 cells resistant to transformation. Pdcd4 inhib-
its transformation and tumorigenesis, in part by specifically
inhibiting AP-1 dependent transcription. The binding partners
of Pdcd4 are not Jun or Fos proteins but are translation initiation
factors eIF4A and eIF4G. Pdcd4 inhibits translation initiation by
directly binding to translation initiation factor eIF4A and inhibit-
ing its helicase activity. The helicase activity of eIF4A is important
for unwinding 5 0UTR structured mRNAs prior to scanning to the
translational start site. Pdcd4 also interferes with scaffold eIF4G
function. Pdcd4 must interact with eIF4A and inhibit translation
in order to inhibit AP-1 transactivation, as Pdcd4 mutants inacti-
vated for eIF4A binding fail to inhibit AP-1. Recent findings with
K14-driven Pdcd4 expression in mice have established that Pdcd4
inhibits translation of a 5 0UTR-structured mRNA as well as
expression of ‘‘translationally repressed’’ proteins. Pdcd4 inhibits
AP-1 dependent transcription and acts to attenuate papilloma-
genesis and papilloma to carcinoma conversion. Moreover Pdcd4
expression (a) is downregulated with progression in several
human cancer sites, (b) confers sensitivity to certain therapeutic
drugs, and (c) suppresses invasion and motility in human cancer
cell lines. Pdcd4 suppresses cancer cell invasion by targeting the
expression of MAP4K1, an upstream regulator of Jun N-terminal
Kinase signaling, with consequent inhibition of AP-1 dependent
transcription. Thus, activating or mimicking the expression of
Pdcd4 might be an attractive preventive or therapeutic strategy.
Enhancing the interaction of Pdcd4 with eIF4A or targeting down-
stream translational targets may produce the ‘‘desired’’ but not
the ‘‘undesired’’ outcomes achieved with mTOR inhibitors. mTOR
inhibitors repress translation by enhancing the interaction of 4E-
BP with cap binding protein eIF4E but are also immunosuppres-
sive. Pdcd4 appears not to show immunosuppressive activity.
Although we and others have identified translationally repressed
candidates, the functionally significant translational targets of
Pdcd4 are still unknown. Knowing these Pdcd4 targets is impor-
tant for designing prevention strategies. In summary, Pdcd4 is
the first suppressor of tumorigenesis and invasion known to
directly inhibit translation initiation. Translation initiation thus
appears to be a promising molecular target for cancer prevention
and intervention.
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S53. THE ISEL AND BR21 TRIALS – OUTCOMES SIMILAR OR
DIFFERENT?
Nick Thatcher. Christie Hospital, Manchester, UK.
The survival effects of EGFR-TKI therapy have been evaluated in
two Phase III placebo-controlled studies in refractory NSCLC: ISEL
(IRESSA Survival Evaluation in Lung cancer no. = 1692) and BR21
(erlotinib no. = 731).1,2 Gefitinib (Iressa) showed some improve-
ment in survival compared with placebo, but the difference did
not reach statistical significance on the prespecified stratified
log rank test required for registration in either the overall popula-
tion (HR 0.89; p = 0.087; median 5.6 vs. 5.1 months) or in patients
with adenocarcinoma (HR 0.84; p = 0.089; median 6.3 vs. 5.4
months). However, preplanned subgroup analyses showed that
gefitinib significantly prolonged survival in patients of Asian eth-
nicity and in patients who had never smoked. The erlotinib BR21
study had a similar design to ISEL, but demonstrated a statisti-
cally significant overall survival benefit for erlotinib HR = 0.7
p < 0.001 median 6.7 vs. 4.7 months.2 However the 95% confidence
intervals for the HRs overlap ISEL 0.77–1.02 and 0.58–0.85 for BR21
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